TY - JOUR
T1 - Antinuclear antibody seropositivity in patients with cutaneous T-cell lymphoma
AU - Peterson, S. R.
AU - Talpur, R.
AU - Duvic, M.
PY - 1998
Y1 - 1998
N2 - Background: We attempted to determine the frequency and clinical relevance of antinuclear antibody (ANA) testing and positive ANA test results in patients with cutaneous T-cell lymphoma (CTCL). Methods: A retrospective chart and computer record review was conducted to determine the frequency of ANA testing in CTCL patients and the rate of seropositivity. Patients with a positive ANA were further examined to define possible explanations of the positive test. Results: Of 381 patients with CTCL, 66 (17%) had ANA tests; 8 of these (12.1%) were found to have an ANA titer greater than or equal to 1:40. Of patients with a positive ANA test, one was found to have chronic cutaneous lupus erythematosus histologically and clinically mimicking CTCL. Others were found to have a comorbid connective tissue disorder, some had apparent drag-induced antinuclear antibodies, and some had no identifiable reason for a positive ANA test. Conclusion: ANA seropositivity does not appear to be increased in CTCL patients, and the ANA test remains a useful screening tool for differentiating between CTCL and connective tissue disorders.
AB - Background: We attempted to determine the frequency and clinical relevance of antinuclear antibody (ANA) testing and positive ANA test results in patients with cutaneous T-cell lymphoma (CTCL). Methods: A retrospective chart and computer record review was conducted to determine the frequency of ANA testing in CTCL patients and the rate of seropositivity. Patients with a positive ANA were further examined to define possible explanations of the positive test. Results: Of 381 patients with CTCL, 66 (17%) had ANA tests; 8 of these (12.1%) were found to have an ANA titer greater than or equal to 1:40. Of patients with a positive ANA test, one was found to have chronic cutaneous lupus erythematosus histologically and clinically mimicking CTCL. Others were found to have a comorbid connective tissue disorder, some had apparent drag-induced antinuclear antibodies, and some had no identifiable reason for a positive ANA test. Conclusion: ANA seropositivity does not appear to be increased in CTCL patients, and the ANA test remains a useful screening tool for differentiating between CTCL and connective tissue disorders.
UR - http://www.scopus.com/inward/record.url?scp=0031671252&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031671252&partnerID=8YFLogxK
U2 - 10.1016/S0190-9622(98)70320-2
DO - 10.1016/S0190-9622(98)70320-2
M3 - Article
C2 - 9738778
AN - SCOPUS:0031671252
SN - 0190-9622
VL - 39
SP - 434
EP - 438
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 3
ER -